Roche Holding AG Stock News

Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, o

Pakistan's drug regulator said on Monday it had temporarily banned the use of a cancer medication distributed by Swiss pharmaceutical company Roche pending an investigation, as 12 patients went blind

Roche's stock price has declined, underperforming its peers, due to the loss of patent protection for its blockbuster drugs, lower Covid-related revenue and several pipeline setbacks. The company has

The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the qu

Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its shares

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th

Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.

Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.

Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.

Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.

Cancer drug stocks were boosted on Wednesday after Roche accidentally published positive interim results from its lung cancer treatment study. The Swiss drugmaker said that it had been made aware of

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,

Swiss drug maker Roche said on Wednesday it had been made aware of an inadvertent disclosure in a study of its new immunotherapy for patients with lung cancer using an experimental class of drugs know

Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a

Roche Holding AG (OTCQX:RHHBY) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Bruno Eschli - Head, Investor Relations Thomas Schinecker - Chief Executive Officer, Roche